Disease · MONDO_0005077

pertussis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. pertussis. Diseases, record MONDO_0005077. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005077

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: pertussis; Open Targets
Open Targets ID: MONDO_0005077; Open Targets
Other names: Bordetella pertussis caused disease or disorder, Bordetella pertussis disease or disorder, Bordetella pertussis infection, Bordetella pertussis infectious disease, whooping cough; Open Targets
Disease Ontology: DOID:1116; Disease Ontology
MeSH: D014917; MeSH
NCI Thesaurus: C85231; NCI Thesaurus
Orphanet: ORPHA:1489; Orphanet
Highest stage of its drugs: Approval, for 9 of its 12 drugs, from DailyMed and TTD; Open Targets

Drugs12

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TETANUS TOXOID	CHEMBL2108875	Vaccine component	Approval	TTD	7	4	3	Drugs and targets
DIPHTHERIA TOXOID	CHEMBL2109121	Vaccine component	Approval	TTD	5	2	2	Drugs and targets
PENTETIC ACID	CHEMBL780	Small molecule	Approval	TTD	4	2	0	Drugs and targets
TECHNETIUM TC 99M PENTETATE	CHEMBL2096656	Small molecule	Approval	TTD	4	2	0	Drugs and targets
BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ	CHEMBL6068348	Vaccine component	Approval	TTD	3	2	1	Drugs and targets
BORDETELLA PERTUSSIS PERTACTIN AUTOTRANSPORTER	CHEMBL6068350	Vaccine component	Approval	TTD	3	2	1	Drugs and targets
HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN	CHEMBL4297973	Vaccine component	Approval	TTD	3	2	1	Drugs and targets
ERYTHROMYCIN	CHEMBL532	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
ERYTHROMYCIN ETHYLSUCCINATE	CHEMBL1200688	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
PERTUSSIS IMMUNE GLOBULIN	CHEMBL2109218		Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 12

See all 12 drugs

Targets1

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes
IL13	Interleukin-13	1	Interleukin-13 inhibitor	Phase 2	https://conductscience.org/library/genes/3596

Source Drugs and targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02853929	Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery	Phase 4	551	2020-01-14	Diphtheria, Hepatitis B, Acellular Pertussis, Haemophilus Influenzae Type b, Tetanus, Poliomyelitis, Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines	BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ, BORDETELLA PERTUSSIS PERTACTIN AUTOTRANSPORTER, DIPHTHERIA TOXOID, HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN, TETANUS TOXOID	Its record names the disease	ClinicalTrials.gov
NCT00304265	Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine	Phase 4	215	2011-04-07	Pertussis, Diphtheria, Tetanus, Poliomyelitis	TETANUS TOXOID	Its record names the disease	ClinicalTrials.gov
NCT03562377	Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)	Phase 2	215	2021-03-05	Atopic Dermatitis	TRALOKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT02408926	Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand	Phase 4	370		Pertussis	DIPHTHERIA TOXOID, TETANUS TOXOID	Its record names the disease	ClinicalTrials.gov
NCT00004422	Intravenous Pertussis Immune Globulin in Patients With Severe Childhood Pertussis Infection	Phase 3	174		Pertussis, Whooping Cough	PERTUSSIS IMMUNE GLOBULIN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials11

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
dTpa Group vs Control Group: Number of Subjects With Unsolicited Adverse Events (AEs)	94 of 263	111 of 277	540	NCT02853929	Trial comparisons
dTpa Group vs Control Group: Number of Subjects With Serious Adverse Events (SAEs)	0 of 263	3 of 277	540	NCT02853929	Trial comparisons
dTpa Group vs Control Group: deaths from any cause	0 of 263	0 of 277	540	NCT02853929	Trial comparisons
dTpa Group vs Control Group: serious adverse events	0 of 263	3 of 277	540	NCT02853929	Trial comparisons
6th Dose Pertussis Vaccine Group vs 5th Dose Pertussis Vaccine Group: serious adverse events	0 of 117	0 of 98	215	NCT00304265	Trial comparisons
Tralokinumab vs Placebo: Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16	33 of 106	21 of 108	214	NCT03562377	Trial comparisons
Tralokinumab vs Placebo: Participants Achieving at Least 75% Reduction in Eczema Area and Severity Index (EASI) at Week 16.	52 of 106	39 of 108	214	NCT03562377	Trial comparisons
Tralokinumab vs Placebo: deaths from any cause	1 of 107	0 of 107	214	NCT03562377	Trial comparisons
Tralokinumab vs Placebo: serious adverse events	3 of 107	3 of 107	214	NCT03562377	Trial comparisons
Tralokinumab vs Placebo: Positive Anti-tetanus Response at Week 16	80 of 87	73 of 76	163	NCT03562377	Trial comparisons

1 to 10 of 11

See all 11 comparisons in its trials

Papers from its trials10

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
20616762	RESULT	1	PubMed
41122946	DERIVED	1	PubMed
39385752	DERIVED	1	PubMed
39066382	DERIVED	1	PubMed
38752802	DERIVED	1	PubMed
37285482	DERIVED	1	PubMed
35135700	DERIVED	1	PubMed
33612341	DERIVED	1	PubMed
32331806	DERIVED	1	PubMed
31418814	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005077

GET https://conductscience.org/api/diseases/v1/MONDO_0005077/drugs

API reference For AI assistants